Pegilodecakin

Summary

Pegilodecakin (CHEMBL3989992) is a phase-3 clinical-stage protein; indicated across 2 conditions including exocrine pancreatic carcinoma and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989992
Name	Pegilodecakin
Type	Protein
Max phase	3

Also known as: AM-0010, AM0010, LY-3500518, LY3500518, Pegilodecakin, Pegilodecakina, Pegilodecakine, PEGILODECAKIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02923921	PHASE3	COMPLETED	Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
NCT03382899	PHASE2	TERMINATED	Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
NCT03382912	PHASE2	TERMINATED	Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
NCT02009449	PHASE1	COMPLETED	A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
NCT03267732	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
NCT03381547	PHASE1	COMPLETED	A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
NCT04194892	PHASE1	COMPLETED	A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants
NCT03554434	Not specified	NO_LONGER_AVAILABLE	An Expanded Access Program for AM0010 (Pegilodecakin)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).